June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Intravitreal Tanibirumab, a Fully Human Monoclonal Antibody against Vascular Endothelial Growth Factor Receptor 2, Suppresses and Regresses Laser-induced Choroidal Neovascularization in a Rat Model
Author Affiliations & Notes
  • Jaeryung Kim
    Ophthalmology, Samsung Medical Center, Seoul, Republic of Korea
  • Sang Ryeol Shim
    PharmAbcine, Inc., Daejeon, Republic of Korea
  • Sung-Woo Kim
    PharmAbcine, Inc., Daejeon, Republic of Korea
  • Weon Sup Lee
    PharmAbcine, Inc., Daejeon, Republic of Korea
  • Jin-San Yoo
    PharmAbcine, Inc., Daejeon, Republic of Korea
  • Sang Hoon Lee
    PharmAbcine, Inc., Daejeon, Republic of Korea
  • Sang Jin Kim
    Ophthalmology, Samsung Medical Center, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships Jaeryung Kim, PharmAbcine, Inc. (F); Sang Ryeol Shim, None; Sung-Woo Kim, PharmAbcine Inc. (F), PharmAbcine Inc. (E), PharmAbcine Inc. (P); Weon Sup Lee, None; Jin-San Yoo, None; Sang Hoon Lee, None; Sang Jin Kim, Daewoo Pharm. (F), Pharmabcine (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3283. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jaeryung Kim, Sang Ryeol Shim, Sung-Woo Kim, Weon Sup Lee, Jin-San Yoo, Sang Hoon Lee, Sang Jin Kim; Intravitreal Tanibirumab, a Fully Human Monoclonal Antibody against Vascular Endothelial Growth Factor Receptor 2, Suppresses and Regresses Laser-induced Choroidal Neovascularization in a Rat Model. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3283.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the effect of intravitreally administered tanibirumab, a fully human monoclonal antibody against vascular endothelial growth factor (VEGF) receptor 2, on a rat model of laser-induced choroidal neovascularization (CNV)

Methods: The anti-angiogenic effects of tanibirumab were validated by rat aortic ring assay. CNV was induced by laser photocoagulation on Day 0 in eyes of Brown Norway rats. Intravitreal injection of tanibirumab or PBS was done on Day 0 (prevention arm) or Day 7 (treatment arm). Seven days after injection, eyes were enucleated and retinal pigment epithelium-choroid-sclera flat mounts were prepared. Areas of CNV were determined in flat mounts using intravenously administered FITC-dextran and TRITC-BS isolectin labeling, and quantified using an image analysis program.

Results: In the rat aortic ring assay, tanibirumab significantly inhibited VEGF-mediated vessel sprouting. In the prevention arm, the mean area of CNV was reduced by 28.2% and 53.9 % in tanibirumab-treated (20ug and 60ug, respectively) eyes compared with PBS-treated control eyes on Day 7 (P=0.028 and <0.001, respectively). In the treatment arm, the mean area of CNV was reduced by 28.7% and 46.0 % in tanibirumab-treated (20ug and 60ug, respectively) eyes compared with PBS-treated control eyes on Day 14 (P=0.020 and <0.001, respectively).

Conclusions: Intravitreally administered tanibirumab resulted in the suppression of formation of new, and regression of pre-formed laser-induced CNV in the rat model. Tanibirumab may be a feasible treatment for CNV associated with age-related macular degeneration or other causes.

Keywords: 412 age-related macular degeneration • 453 choroid: neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×